Pharmacotherapy for neurogenic lower urinary tract dysfunction
|
|
- George Horton
- 6 years ago
- Views:
Transcription
1 Pharmacotherapy for neurogenic lower urinary tract dysfunction Prof. Enrico Finazzi Agrò Unit of Functional Urology Tor Vergata University Hospital S. Lucia Rehabilitation Hospital Rome, ITALY
2 Enrico Finazzi Agrò Affiliations to disclose: Enter Organisation/Relationship Funding for speaker to attend: Enter X in appropriate box Self-Funded Institution (non-industry) funded X Sponsored by: ICS
3
4 ANTIMUSCARINIC AGENTS
5 Antimuscarinic drugs on the market Oxybutynin (IR mg/day, IR 15 mg/day, TDS mg/day) Tolterodine (IR 2mg/day, IR 4 mg/day, ER 4mg/day) Propiverine, (IR 30mg/die, IR 45 mg/die, ER 20mg/die, ER 30 mg/die) Trospium, (40mg/die) Solifenacin (5mg/day, 10 mg/day) Darifenacin (7.15 mg/day, 15 mg/day) Fesoterodine (4 mg/day, 8 mg/day) Novara G., et al., Eur Urol, 2008
6 - - Membr. Cell. M 2 M 3 3 AC PLC + + camp Ca 2+ IP 3 relaxation contraction Ca 2+ contraction Chapple CR. Urology. 2000;55:33-46
7 In the denervated rat bladder, there is a 60% increase in M2 receptor density and these M2 receptors provide some contractile function. Braverman AS: Am J Physiol 1998 In the human bladder with NGB M2 receptors were found to mediate contractions in one study, but were found to play no part in bladder contractions in another. Pontari MA: Am J Physiol Regul Integr Comp Physiol 2004 Stevens LA: Eur Urol 2007
8 Thirty studies (16 RCT), 1479 patients Efficacy of AM in NDO, following 2 3 weeks of treatment no placebo effects manifested.
9 Other important parameters (impact on the upper urinary tract, continence, post-void residual urine, catheterization, urinary tract infections and quality of life) investigated to a limited extent only. Incidence rates of adverse events were comparable for NDO and IDO.
10 Most of the studies, especially RCT, were undertaken with oxybutynin immediate release (IR), trospium chloride IR, propiverine IR and propiverine extended release. In NDO, these drugs are best investigated.
11 Solifenacin 10mg significantly improved mean change from baseline MCC versus placebo (P<0.001) and was associated with improvements in bladder volume at first contraction and at first leak as well as detrusor pressure at first leak. Patient perception of bladder condition significantly improved with solifenacin 10mg versus placebo (P<0.041).
12 [NOME CATEGORIA]S [PERCENTUALE] [NOME CATEGORIA]S [PERCENTUALE]
13 [NOME CATEGORIA]S [PERCENTUALE] [NOME CATEGORIA]S [PERCENTUALE]
14 In the NGB population higher doses are required compared to the non-neurogenic population to be effective. Intravesical administration also used Bennett N: J Urol 2004 Buyse G: J Urol 1998
15 Dual therapy with AM Dual therapy (between combinations of oxybutynin, tolterodine and trospium) has been shown to be effective and well tolerated in a few patients with neurogenic bladder dysfunction Amend B et al Eur Urol. 2008
16 Safety and tolerability
17
18 Oxybutynin associated with cognitive deficits MS and probably stroke and Parkinson s diseases pts may have an increase in permeability of BBB. New evidence that higher cumulative antimuscarinic usage is associated with an increase in the incidence of dementia and Alzheimer s Gray SL: JAMA Intern Med 2015
19 Prescriptions, in thousands Despite the Evidence, Fewer Men than Women Are Treated with Antimuscarinics OAB prescriptions BPH prescriptions Female Male 4 Times fewer OAB prescriptions are written for men Male Men with LUTS are treated mainly for prostate conditions Data collected over 12 months. OAB prescriptions include all antimuscarinics. BPH prescriptions include all alpha-blockers and 5- ARIs. Verispan Patient Longitudinal Data, MAT IMS NPA, MAT
20
21
22 Safety of Tolterodine IR in Men with OAB/DO and BOO: AEs Urinary Symptom AEs Placebo (n = 72) Tolterodine IR (n = 149) n % n % Micturition disorder Urinary tract infection Dysuria Micturition frequency Micturition urgency Strangury AUR Bladder discomfort Urethral disorder Urinary incontinence Overall AE = adverse event. Abrams P et al. J Urol. 2006;175:
23 TIMES: Change in PVR Parameter Placebo (N = 215) Tolterodine ER (N = 210) Tamsulosin (N = 209) Tolterodine ER/ Tamsulosin (N = 217) Mean at baseline Mean at week Mean change to week
24 Significance of PVR PVR and Antimuscarinics in men It is common belief that antimuscarinics should not be used in men with BOO for a potential of AUR. Some placebo controlled clinical trial data suggest that antimuscarinics (alone or in combination with an alphablocker) do not increase the risk of AUR and do not produce a clinically significant increase of PVR in men, even in presence of BPO. Roehrborn CG,et al. Urology Nov;72(5):1061-7; discussion Athanasopoulos A, et al. Eur Urol Jul;60(1): However, patients with significant PVR were excluded from these studies and the safety of antimuscarinics in men remains to be confirmed. Teaching Module 24
25 Most studies recommend not utilizing AM drugs in patients with PVR >200 cc
26 MIRABEGRON
27 - - Membr. Cell. M 2 M 3 3 AC PLC + + camp Ca 2+ IP 3 relaxation contraction Ca 2+ contraction Chapple CR. Urology. 2000;55:33-46
28 Other drug classes to treat OAB? Despite intensive research, few new therapeutic principles have emerged and been demonstrated to have sufficient efficacy and adverse effect profiles to be accepted for approval and clinical use 1 Research indicated that stimulation of β 3 -receptors leads to bladder relaxation Discovery of β 3 -adrenoceptors, predominately present on the bladder wall development of β 3 -adrenoceptor agonist FDA-approval β 3 -agonist First FDA-approved antimuscarinic agent Andersson KE. Curr Urol Rep 2013;doi: /s ; 2. Kennelly MJ Rev Urol 2010;12:12-9; 3.
29
30 EAU guidelines 2016
31 31
32 Nitti VW et al. J Urol 2013; 190:
33 Mirabegron in BOO pts. Bladder Contractility Index Bladder Voiding Efficiency Nitti VW et al. J Urol 2013; 190:
34 American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2012) Drugs with strong anticholinergic properties Antihistamines Antiparkinson agents Skeletal muscle relaxants Brompheniramine Chlorpheniramine Cyproheptadine Diphenhydramine Loratadine Antidepressants Carbinoxamine Clemastine Dimenhydrinate Hydroxyzine Meclizine Benztropine Trihexyphenidyl Antipsychotics Carisoprodol Cyclobenzaprine Orphenadrine Tizanidine Amitriptyline Clomipramine Doxepin Nortriptyline Protriptyline Amoxapine Desipramine Imipramine Paroxetine Trimipramine Antimuscarinics (urinary incontinence) Darifenacin Flavoxate Solifenacin Trospium Fesoterodine Oxybutynin Tolterodine Chlorpromazine Fluphenazine Olanzapine Pimozide Promethazine Thiothixene Antispasmodics Atropine products Belladonna alkaloids Dicyclomine Homatropine Hyoscyamine products Propantheline Scopolamine Clozapine Loxapine Perphenazine Prochlorperazine Thioridazine Trifluoperazine
35
36 Mirabegron was well tolerated in older OAB patients with no difference in tolerability with age over a 1-year period. UTI and hypertension were the most frequent AE found in the population. However, in elderly subjects, these AE were more frequent in people treated with tolterodine than those under mirabegron over 12 months
37
38 Nota Informativa Importante su mirabegron: nuove raccomandazioni relative al rischio di aumento della pressione arteriosa Pillole dal Mondo n /09/2015 L uso di mirabegron è ora controindicato nei pazienti affetti da ipertensione grave non controllata, intesa come Pressione Arteriosa Sistolica 180 mmhg e/o Pressione Arteriosa Diastolica 110 mmhg. È, quindi, necessario misurare la pressione arteriosa prima di intraprendere il trattamento e monitorarla regolarmente durante lo stesso, specialmente nei pazienti affetti da ipertensione
39
40 Mirabegron CV Tolerability Pooled 12-week Phase III Studies (046, 047 and 074) CV Events Placebo (n=1380) 25mg (n=432) Mirabegron 50mg (n=1375) 100mg (n=929) Tolterodine ER 4mg (n=495) Incidence, n(%) of APTC/MACE 4 (0.3) (0.2) Relative risk of APTC/MACE (95% CI) - NE NE NE - 1-year Phase III Study (049) CV Events Mirabegron Tolterodine ER 4mg (n=812) 50mg (n=812) 100mg (n=820) Incidence, n(%) of APTC/MACE 6 (0.7) * 0 4 (0.5) ** Relative risk of APTC/MACE (95% CI) 1.50 (0.35, 7.27) NE - NE = not evaluated due to insufficient data * nonfatal stroke (3 patients), nonfatal myocardial infarction (2 patients) and CV death (1 patient) ** CV death (2 patients), nonfatal myocardial infarction (1 patient) and nonfatal stroke (1 patient) Rosa et al., Eur Urol Eur Urol Feb;69(2):311-23
41 The CV safety of mirabegron appears to be acceptable at therapeutic doses and comparable with that of antimuscarinic agents
42 ADD ON THERAPY?
43 ADD ON THERAPY? Incontinence episodes
44 DESMOPRESSIN
45 Spinal cord injured patients often have high urine output at night, particularly those with higher level lesions. Szollar S: Paraplegia 1995 Rule out UTI and glucosuria, congestive heart failure, improper timing of diuretic administration, sleep apnea and renal failure
46 Desmopressin Optimize bladder management Restrict fluids before bed Perform voiding diary Desmopressin treatment evaluated in few studies on SCI and MS patients with favorable results.
47 Desmopressin Check renal function and sodium levels Start with 120 mcg/day (in adults) Check sodium level and blood pressure frequently Not indicated for patients >65 years
48 ALPHA-BLOCKERS
49 1-receptors
50 Q max (ml/s) Alfa-blockers: Quick Qmax increase ,5* Alfuzosina 10 mg ,3 9,4 Placebo 6 4 Basal 8 hours *p=0, Mod. da Marks LS et al. Urology 2003; 62:
51 IPSS Alfa-blockers: LUTS improvement 0 *p<0,001 vs basale * -32% vs basale -6 * * * -7-8 Basal (n=2.777) M3 (n=2.662) M6 (n=2.385) M9 (n=1.575) M12 (n=2.055) Visite 8. Van Moorselaar RA et al. BJU Int 2005; 95:
52 Alpha-Blockers (filling phase) Can both improve storage and emptying symptoms in patients with NGB. Terazosin 5 mg showed good urodynamic improvement (reduction of detrusor pressure during filling) in a small group of SCI patients Swierzewski SJ J Urol 1994
53 Alpha-Blockers (voiding phase) In individuals who can spontaneously void alpha blockers have been shown to be effective. Symptomatic and urodynamic improvement in pts with DSD, SCI and MS. Stankovich E: Urologiia 2004 Kakizaki H: Int J Urol 2003 O'Riordan JI: J Urol 1995
54 Alpha-Blockers (autonomic dysr.) Terazosin has been shown to reduce the frequency of autonomic dysreflexia episodes and the severity of the symptoms in SCI pts with only minor side effects of fatigue and dizziness Chancellor MB: J Urol 1994
55 Conclusions
56
Supplementary Online Content
Supplementary Online Content Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. Published online January
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Drugs in Older Adults: Beers Criteria Heather Sakely,
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationQuality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Quality ID #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationNatural Medicines Food-Drug Interactions and Other Interesting Stuff
Natural Medicines Food-Drug Interactions and Other Interesting Stuff Homeopathy Like treats Like More dilute = More potent Potentization serial dilutions Forrest Batz, PharmD Assistant Professor of Pharmacy
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationDrug Class Review on Overactive Bladder Drugs
Drug Class Review on Overactive Bladder Drugs Preliminary Scan Report #1 February 2014 Last Summary Review (June 2013) The Agency for Healthcare Research and Quality has not yet seen or approved this report
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationKatee Kindler, PharmD, BCACP
Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,
More informationAUA & EAU Update on BPH & LUTS - Medical Management - DongGuk University Seo Young Jin
AUA & EAU Update on BPH & LUTS - Medical Management - DongGuk University Seo Young Jin Abstracts for BPH and Nocturia 1. Alpha blockers (3 abstracts) - Silodosin, Alfuzosin EAU 999, 1000, 1002 2. 5-alpha
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationLUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group
LUTS in the modern era Dr Jon Rees Tyntesfield Medical Group In the past! Man with urinary symptoms = PROSTATISM Prostatism = TURP TURP unsuccessful = REDO TURP Redo TURP unsuccessful = can t help you!
More informationRational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP
Rational Pharmacotherapy for LUTS in Older People Dr William Gibson MBChB MRCP Frailty Frailty = state of increased vulnerability resulting from agingassociated decline in reserve and function NOT synonymous
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationDrugs for the overactive bladder: are there differences in persistence and compliance?
Editorial Drugs for the overactive bladder: are there differences in persistence and compliance? Karl-Erik Andersson 1,2 1 Institute for Regenerative Medicine, Wake Forest University School of Medicine,
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationMale Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon
Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS
More informationPotentially Inappropriate Medication Use in Older Adults 2015 Latest Research
Home Resources Potentially Inappropriate Medication Use in Older Adults 2015 Resources Potentially Inappropriate Medication Use in Older Adults 2015 Latest Research Drugs and Categories of Drugs What these
More informationOAB Treatment Guidelines
OAB Treatment Guidelines This Practice Aid has been provided as a quick reference to help learners apply the information to their daily practice and care of patients. It is part of the activity Overcoming
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationMichael Organ PGY2 Urology Major Presentation 2011
Michael Organ PGY2 Urology Major Presentation 2011 1 Epidemiology Pathophysiology Evaluation and Diagnosis Treatments -General -Nocturnal Polyuria -BPH -OAB Conclusion 2 Nocturia is the complaint that
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationMuscarinic receptor antagonists for overactive bladder
Great drug classes ANTIMUSCARINIC DRUGS FOR OAB From time to time we publish a full review of drugs that are available for the treatment of common conditions. In this issue, the review is written by two
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationThe Neurogenic Bladder
The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder
More informationUrinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationManagement, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence
Management, Evaluation, and Treatment of Overactive Bladder and Urinary Incontinence Arthur Mourtzinos, MD, MBA Co-Vice Chair, Institute of Urology Director, Continence Center Assistant Professor of Urology,
More informationEAU meeting report March 2016 Munich, Germany
EAU meeting report 11-15 March 2016 Munich, Germany 2 EAU meeting report 11-15 March 2016 Munich, Germany At this year s European Association of Urology (EAU) in Munich there were around 13,000 participants
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationGeriatric Urinary Incontinence
Geriatric Urinary Incontinence Neil M. Resnick, MD Thomas Detre Professor of Medicine Chief, Division of Geriatric Medicine University of Pittsburgh/UPMC UI: The Problem Prevalence in elderly 33% Morbidity
More informationDementia Pharmacotherapy
Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on
More informationIntroduction. EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder. Can J Urol 2016;23(Suppl 1):2-9.
Renu S. Eapen, MD, Sidney B. Radomski, MD Division of Urology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada EAPEN RS, RADOMSKI SB. Gender differences in overactive bladder.
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2015 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:
More information5 Conservative Treatment for. Pelvic Floor Disorders
5 Conservative Treatment for Pelvic Floor Disorders 23 Pharmacologic Approach to Urinary Incontinence and Voiding Disorders K.-E. Andersson Introduction The main components of the lower urinary tract,
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationUrogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationEfficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies
702797TAU0010.1177/1756287217702797Therapeutic Advances in UrologyA. Tubaro research-article2017 Therapeutic Advances in Urology Original Research Efficacy and safety of daily mirabegron 50 mg in male
More informationMirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year
bs_bs_banner International Journal of Urology (2014) 21, 960 967 doi: 10.1111/iju.12568 Review Article Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: An overview of efficacy
More informationLong-term persistence with mirabegron in a real-world clinical setting
International Journal of Urology (2018) 25, 501--506 doi: 10.1111/iju.13558 Original Article: Clinical Investigation Long-term persistence with in a real-world clinical setting Naoki Wada, Masaki Watanabe,
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 158 165 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Christian Gratzke and Karl-Erik Andersson
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationIndividualizing medical treatment of overactive bladder
Review Article Tzu Chi Medical Journal 2018; 30(4): 195 199 Individualizing medical treatment of overactive bladder Hann Chorng Kuo a,b* a Department of Urology, Buddhist Tzu Chi General Hospital, Hualien,
More informationBPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG FECSM Beaconsfield Medical Practice, Brighton & Brighton & Sussex Universities NHS Trust As man draws near the common goal Can anything be sadder Than he
More informationFemale Urinary Incontinence
Primary Care Internal Medicine Female Urinary Incontinence May Wakamatsu, MD MGH Vincent Obstetrics & Gynecology Dept Division of Female Pelvic Medicine & Reconstructive Surgery 2015 Female Urinary Incontinence
More informationMedical management of neurogenic bladder with oral therapy
Review Article Medical management of neurogenic bladder with oral therapy Anne P. Cameron Department of Urology, University of Michigan, Ann Arbor, Michigan, USA Correspondence to: Anne P. Cameron, MD,
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationGeriatric Giants Lecture Series: Urinary incontinence
Geriatric Giants Lecture Series: Urinary incontinence Learning objectives To demonstrate an understanding of : definition of urinary incontinence physiological control of the micturition cycle changes
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August
BRAND NAME Noctiva GENERIC NAME Desmopressin acetate nasal spray MANUFACTURER Serenity Pharmaceuticals DATE OF APPROVAL March 3, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationPelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS
Pelvic Floor Therapy for the Neurologic Client Carina Siracusa, PT, DPT, WCS OhioHealth, Columbus Ohio Disclosures I have nothing to disclose Objectives Describe the role of a pelvic floor therapist in
More informationImproving Diagnosis and Treatment of OAB Through Screening, Defining Goals and Customizing Treatment
Improving Diagnosis and Treatment of OAB Through Screening, Defining Goals and Customizing Treatment Pamela Ellsworth, MD Professor of Urology UMassMemorial Medical Center/University of Massachusetts Medical
More informationAcute Urinary Retention
Acute Urinary Retention An Integrated Care Pathway of the Collaborative Care Network Subject Matter Expert: Kent Krejci, MD Pathway Custodian: Pat Czapp, MD First, a Friendly Reminder... This Integrated
More informationLUTS & Cancer pathway. Mr Francis Thomas Urology Consultant DRI &BDGH
LUTS & Cancer pathway Mr Francis Thomas Urology Consultant DRI &BDGH Topics Male and female LUTS Urinary retention Post void Residual urine Referral pathway LUTS Raised PSA Hematuria Services in community
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationUrinary Incontinence. Lee A. Jennings, MD, MSHS. Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center
Urinary Incontinence Lee A. Jennings, MD, MSHS Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center Slides adapted from Alison Moore, MD, MPH University of
More informationMeasure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety
Measure #238 (NQF 0022): Use of High-Risk Medications in the Elderly National Quality Strategy Domain: Patient Safety 2016 PHYSICIAN QUALITY REPORTING OPTIONS FOR INDIVIDUAL MEASURES REGISTRY ONLY DESCRIPTION:
More informationLUTforum Highlights Christian Gratzke LMU Munich
LUTforum Highlights 2015 Christian Gratzke LMU Munich What is LUTforum? Web-based platform to provide specialists with highlights in functional urology presented at major urological congresses PowerPoint
More informationWho Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
LUTS (2013) 5, 145 149 ORIGINAL ARTICLE Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign rostatic Hyperplasia? Jun OBATA, Kazuhiro
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More information